Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencing

Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencing

Objetives The aim of this study was to identify CMV drug resistance mutations (DRM) in solid organ transplant (SOT) recipients with suspected resistance comparing next-generation sequencing (NGS) with Sanger sequencing and assessing risk factors and the clinical impact of resistance. Methods Using S...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: López-Aladid, Rúben, Guiu, Alba, Mosquera, María Mar, López-Medrano, Francisco, Cofan, Frederic, Linares, Laura, Torre-Cisneros, Julián, Vidal, Elisa, Moreno Camacho, Asunción, Aguado, José María, Cordero, Elisa, Martin-Gandul, Cecilia, Carratalà, Jordi, Sabé, Núria, Niubó, Jordi, Cervera, Carlos, Capón, Alicia, Cervilla, Anna, Santos, Marta, Bodro, Marta, Muñoz, Patricia, Fariñas, María Carmen, Antón, Andrés, Aranzamendi Zaldumbide, Maitane, Montejo, Miguel, Pérez-Romero, Pilar, Len, Oscar, Marcos, María Ángeles, Universitat Autònoma de Barcelona
Format: Artikel
Sprache:eng
Schlagworte:
Cytomegalovirus
Drug Resistance, Viral
Female
Genes, Viral
High-Throughput Nucleotide Sequencing
Humans
Male
Middle Aged
Mutation
Transplant Recipients
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objetives The aim of this study was to identify CMV drug resistance mutations (DRM) in solid organ transplant (SOT) recipients with suspected resistance comparing next-generation sequencing (NGS) with Sanger sequencing and assessing risk factors and the clinical impact of resistance. Methods Using Sanger sequencing as the reference method, we prospectively assessed the ability of NGS to detect CMV DRM in the UL97 and UL54 genes in a nationwide observational study from September 2013 to August 2016. Results Among 44 patients recruited, 14 DRM were detected by Sanger in 12 patients (27%) and 20 DRM were detected by NGS, in 16 (36%). NGS confirmed all the DRM detected by Sanger. The additional six mutations detected by NGS were present in